Celgene, Sutro Biopharma Agree on Potential $500 Million Deal

Biotech company Sutro Biopharma announced in a press release that it will be collaborating with Celgene (NASDAQ: CELG  ) on a deal  to develop antibody drug conjugates (ADCs) and bispecific antibodies for undisclosed targets. The agreement, which could be worth up to $500 million if the program succeeds, will also have the two companies working on manufacturing a proprietary antibody for Celgene.

Sutro will pick up an upfront payment of a "substantial" sum, according to the release, as well as equity investment in the company and payouts for hitting program milestones. Sutro could also receive royalties on any drug sales from Celgene if the program is a success.

Sutro CEO William Newell added his take on the agreement, saying in the release:

The scope of this partnership showcases our novel, cell-free approach to designing, developing and manufacturing next-generation ADCs and bispecific antibodies.

Sutro will handle product design and will produce pre-clinical material as part of the program. Celgene and Sutro's deal comes after several other companies  have looked into producing ADCs, including a partnership between Abbot Labs (NYSE: ABT  ) and Seattle Genetics. Menarini and Oxford BioTherapeutics recently also signed a deal to develop ADCs that could be worth more than $1 billion.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2164983, ~/Articles/ArticleHandler.aspx, 12/20/2014 9:34:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement